echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > 1.5 billion blood lipid-lowering drugs! China Resources Double Crane has been evaluated

    1.5 billion blood lipid-lowering drugs! China Resources Double Crane has been evaluated

    • Last Update: 2020-11-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Today (November 2), the official website of the State Drug Administration shows that China Resources Shuanghe Pharmaceuticals' pivastatin calcium tablets are evaluated consistently by generic drugs.
    2019, sales of pivastatin at public medical institutions in China exceeded 1.5 billion yuan, up 47.50 percent year-on-year, according to the company's internal data.
    pyvastatins, used to treat hypercholesterolemia and familial hypercholesterolemia, are third-generation statins, have lower effective doses than other marketed statins, and have the characteristics of the drug metabolase P450 (CYP) metabolism (CYP2C9 has very little metabolism) that is barely liver-free, reducing possible drug interactions. according to
    meters of intranet data, in 2019, China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal pivastatin sales exceeded 1.5 billion yuan, an increase of 47.50 percent year-on-year.
    , China Resources Shuanghe accounted for 43.56 percent of the market share, Wanbang Pharmaceuticals accounted for 20.75 percent, Beijing-New Pharmaceuticals accounted for 16.06 percent.
    2019 China's public medical institutions terminal Pivastatin brand pattern Source: Minet China's public medical institutions terminal competition pattern of the current domestic market Pivastatin products have pivastatin calcium tablets, pivastatin calcium dispersion tablets.
    pivastatin calcium tablets manufacturers have Japan Xinghe, Xinlitai, Qidu Pharmaceuticals, China Resources Shuanghe, Changao Pharmaceuticals, Wanbang Pharmaceuticals and other 5;
    pyvastatin for the third batch of harvested varieties.
    previously, Xinlitai, Changao Pharmaceuticals, Wanbang Pharmaceuticals of pivastatin calcium tablets have been evaluated and successfully collected, China Resources double crane for the species of the fourth over-evaluation enterprises.
    source: MiNet Database, NMPA
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.